Antiangiogenic Therapy in the Management of Solid Tumors: Current Concepts and Strategies

prIME Oncology invites you to view these expert interviews, along with interactive clinical scenarios and downloadable slides, focusing on antiangiogenic therapeutic advancements in the management of metastatic breast, lung, and colorectal cancers, as well as glioblastoma multiforme, which provide valuable perspectives on recent data.

		Expert Interviews
		Clinical Cases
		Downloadable Slides

Release Date
November 22, 2010

Expiration Date
November 22, 2011

Faculty
Scott Berry, MD, BSc, MHSc, FRCPC
Toronto-Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada

Lucio Crinò, MD
Perugia Hospital
Perugia, Italy

Rebecca Dent, MD
Toronto-Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada

Roman Perez-Soler, MD
Montefiore Medical Center
Bronx, New York, United States

Cornelis J. A. Punt, MD, PhD
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, the Netherlands

Jeffrey Raizer, MD
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States

Sunil Verma, MD, MSEd, FRCPC
Toronto-Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada

Wolfgang Wick, MD, PhD
University of Heidelberg and German Cancer Research Center
Heidelberg, Germany

Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with cancer.

Overview
These expert interviews filmed at the 35th ESMO Congress in Milan, Italy, along with clinical scenarios and downloadable slides, focus on compelling advancements in the areas of metastatic breast, lung, and colorectal cancers, as well as glioblastoma multiforme, and provide perspectives on recent practice changing data.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

Discuss the most recent clinical trial data for antiangiogenic therapy in glioblastoma and non-small cell lung, breast, and colorectal cancers.
Compare and contrast the efficacy and tolerability of various antiangiogenic strategies.
Evaluate the practical utility and clinical implementation of antiangiogenic agents based on data from clinical studies.
Identify areas of uncertainty or controversy requiring further clarification regarding antiangiogenic agents in the management of glioblastoma and lung, breast, and colorectal cancers.

Sponsorship Statement
This activity is sponsored by prIME Oncology.

Accreditation Statement
prIME Onoclogy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement
prIME Oncology designates this enduring internet-based activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:
• Metastatic colon cancer (Punt/Berry) [2010589-01]: 0.25 CME credits
• Glioblastoma multiforme (Raizer/Wick) [2010589-02]: 0.25 CME credits
• Metastatic breast cancer (Verma/Dent) [2010589-03]: 0.25 CME credits
• Metastatic lung cancer (Perez-Soler/Crino) [2010589-04]: 0.25 CME credits

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

Links to the post-tests are available on the activity selection page and video player pages.

Technical Requirements
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.

Estimated time to complete activity: 1.0 hours

Support Statement
This activity is supported by an unrestricted grant from F. Hoffmann-La Roche Ltd.

Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

FACULTY

Dr Berry has disclosed that he has received CME speaking fees from F. Hoffmann-La Roche Ltd. This relationship will not impact his ability to present an unbiased discussion.

Dr Crino has disclosed that he does not have any real or apparent conflicts of interest to report.

Dr Dent has disclosed that she has received consulting fees from AstraZeneca Pharmaceuticals LP; F. Hoffmann-La Roche Ltd.; and sanofi-aventis. None of these relationships will impact her ability to present an unbiased discussion.

Dr Perez-Soler has disclosed that he has received consulting fees from Eli Lilly and Company; Genentech BioOncology; and F. Hoffmann-La Roche Ltd. None of these relationships will impact his ability to present an unbiased discussion.

Dr Punt has disclosed that he has received consulting fees from F. Hoffmann-La Roche Ltd. and MERCK & CO., Inc. None of these relationships will impact his ability to present an unbiased discussion.

Dr Raizer has disclosed that he has received consulting fees from Genentech BioOncology. He has also received fees for non-CME services (eg, speakers’ bureaus) from Genentech BioOncology and MERCK & CO., Inc. None of these relationships will impact his ability to present an unbiased discussion.

Dr Verma has disclosed that he has received consulting fees and performed contracted research from F. Hoffmann-La Roche Ltd and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.

Dr Wick has disclosed that he has received consulting fees from AstraZeneca Pharmaceuticals LP; F. Hoffmann-La Roche Ltd.; and Merck Sharp and Dohme. He has also performed contracted research for MERCK & CO., Inc.; Merck Sharp and Dohme; and Schering-Plough Corporation.

PLANNERS
Janelle Bowersox, RN, MSN, OCN (clinical) – no real or apparent conflicts of interest
Nathan Kelly, PhD (clinical) – no real or apparent conflicts of interest
Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
Susan H Yarbrough, CCMEP (compliance) - no real or apparent conflicts of interest

Disclosure of Unlabeled Use
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.